US-based biotechnology firm Ocugen to open R&D centre in Telangana
Ocugen India Project Manager Dr. Ajay Potluri was delighted to establish the company’s R&D centre in Telangana
By Newsmeter Network Published on 18 May 2023 1:37 PM GMT
Hyderabad: The US-based Ocugen plans to build a research and development (R&D) facility in Telangana that will concentrate on creating cutting-edge vaccines and regenerative cell treatments that tackle unmet medical needs.
The announcement was made following a meeting in New York between Telangana minister K.T. Rama Rao and Dr. Arun Upadhyay, chief scientific officer, head of research, development, and medical at Ocugen; Dr. Shankar Musunuri, chairman, CEO, and co-founder of Ocugen; and Dr. Ajay Potluri, in charge of the Ocugen India Project. The meeting was also attended by Shakthi M. Nagappan, chief executive officer of Telangana Life Sciences, and Jayesh Ranjan, principal secretary, of industries and commerce.
Ocugen Inc., a biotechnology business based in Pennsylvania, is dedicated to identifying, creating, and commercialising novel therapeutic approaches that will enhance patient care and provide hope for patients all over the world.
Dr. Shankar Musunuri said, “We look forward to expanding operations in India and starting to transform Ocugen into a truly global organisation as we pursue new approaches to medicine—being bold and thinking differently with patients at the centre of everything we do. We are appreciative of the chance, and working with the Telangana government has been a joy.”
KTR welcomed Ocugen in Hyderabad with enthusiasm. “This is evidence of the state’s thriving biotech sector and its solid academic foundation, which have drawn both national and international businesses to open R&D facilities. We had identified complex manufacturing and advanced therapeutics as key pillars for growth as part of our 2030 vision to become a US$ 250 billion ecosystem, and I believe that this investment focused on growth and that this investment focused on cell and gene therapy is strategic in nature to drive growth in emerging areas of Life Sciences,” he said.
Dr. Arun Upadhyay added, “Opening an R&D facility in India opens up a market for the development of next-generation genetic and regenerative therapies to meet unmet medical needs. While we continue to enhance the development of therapeutic candidates at Ocugen, I am eager to collaborate with the strong scientific and medical communities in Hyderabad. Our upcoming Indian colleagues will be a great asset to the Ocugen team.”
Ocugen India Project Manager Dr. Ajay Potluri was delighted to establish the company’s R&D centre in Telangana.
